Pulling SEC filings + quote and writing the call…
ACRS
Aclaris Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.16 EPS, $1.41M rev
Last earnings +1.7% on 2026-05-07
$4.87
▲ +8.22%$4.50▲ +212.50%
over 1Y
L $1.39EODHDH $5.09
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+8.2%
1W+3.0%
1M+1.1%
3M+20.3%
YTD+56.3%
1Y+212.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.56x); but revenue fell -58.2% YoY.
Aclaris Therapeutics, Inc. shows $7.83M in FY2025 revenue (-58.2% YoY), a -829.6% net margin, and -63.0% ROE.
Sources: SEC EDGAR (CIK 0001557746, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 4:26:09 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.